Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-10-01
J
Jorge Saucedo
Sourced from institutional research profiles (UAMS TRI or ARA).
Department Chairperson
36 h-index
126 pubs
6,209 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Jorge Saucedo's research investigates interventions and outcomes related to cardiovascular diseases. His work has examined the effectiveness of drug-coated balloons for coronary artery disease and explored the use of vascular endothelial growth factor for angiogenesis in peripheral arterial disease. Saucedo has also studied therapeutic angiogenesis with recombinant fibroblast growth factor-2 in patients with intermittent claudication.
Further research has focused on management strategies for acute coronary syndromes, including the utilization of early invasive approaches for high-risk patients. Saucedo has also investigated the short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease, particularly concerning the use of evidence-based therapies. His publications also address trends and outcomes of restenosis following coronary stent implantation and the correlation between point-of-care measured platelet inhibition and adverse cardiac events after percutaneous coronary intervention.
Saucedo leads a research group and has a notable publication record with an h-index of 36 and over 6,200 citations. His research has been supported by various funding sources, although specific grant details are not provided here. He has collaborated with numerous researchers throughout his career.
Metrics
- h-index: 36
- Publications: 126
- Citations: 6,209
Selected Publications
-
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease (2026)
-
AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review (2026)
-
Implementing the GWTG‐CAD Program in Mexico: Feasibility, Challenges and Lessons Learned for Acute and Secondary Prevention and Management (2026)
Collaboration Network
Top Collaborators
J. David Talley
University of Arkansas for Medical Sciences (US)
6 shared publications
- Surgical complications from hemostatic puncture closure devices
- Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)
- Relation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry report)
- Atorvastatin Versus Revascularization Treatment (AVERT): Fact or fancy?
- Progress in Interventional Cardiology
Showing 5 of 6 shared publications
Robert J. Lederman
Michigan Medicine (US)
3 shared publications
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
- Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial
- Implications of smoking status on the response to therapeutic angiogenesis in peripheral artery disease: findings from the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial
Farrell O. Mendelsohn
3 shared publications
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
- Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial
- Implications of smoking status on the response to therapeutic angiogenesis in peripheral artery disease: findings from the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial
Brian Herb Annex
Duke University (US)
3 shared publications
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
- Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial
- Implications of smoking status on the response to therapeutic angiogenesis in peripheral artery disease: findings from the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial
Luis Andres Garza
University of Arkansas Medical Center (US)
3 shared publications
- Can we prevent in-stent restenosis?
- Comparative Pharmacodynamic Evaluation of Eptifibatide and Abciximab in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: The TAM2 Study
- Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study)
JACK MCKEE
University of Arkansas for Medical Sciences (US)
2 shared publications
- Surgical complications from hemostatic puncture closure devices
- IT FITS! (Intelligence Transfer: From Images to Solutions) Catheter‐Induced Spasm of the Left Main Coronary Artery
Elizabeth D. Kennard
University of Pittsburgh (US)
2 shared publications
- Relation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry report)
- Importance of lesion length on new device angioplasty of native coronary arteries
Martin B. Leon
MedStar Washington Hospital Center (US)
2 shared publications
- Long-term clinical events following creatine kinase–myocardial band isoenzyme elevation after successful coronary stenting
- Relation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry report)
Donald S. Baim
Beth Israel Deaconess Hospital (US)
2 shared publications
- Relation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry report)
- Importance of lesion length on new device angioplasty of native coronary arteries
James Bernard Hermiller
2 shared publications
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
- Implications of smoking status on the response to therapeutic angiogenesis in peripheral artery disease: findings from the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial
Thomas E. Moon
2 shared publications
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
- Implications of smoking status on the response to therapeutic angiogenesis in peripheral artery disease: findings from the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial
M.J. Whitehouse
2 shared publications
- Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
- Implications of smoking status on the response to therapeutic angiogenesis in peripheral artery disease: findings from the therapeutic angiogenesis with FGF-2 for intermittent claudication (TRAFFIC) trial
Alexandra J. Lansky
MedStar Washington Hospital Center (US)
2 shared publications
- Long-term clinical events following creatine kinase–myocardial band isoenzyme elevation after successful coronary stenting
- Importance of lesion length on new device angioplasty of native coronary arteries
Mary V. Jacoski
University of Tennessee Health Science Center (US)
2 shared publications
- Comparative Pharmacodynamic Evaluation of Eptifibatide and Abciximab in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: The TAM2 Study
- Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study)
Lisa K. Jennings
University of Tennessee Health Science Center (US)
2 shared publications
- Comparative Pharmacodynamic Evaluation of Eptifibatide and Abciximab in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: The TAM2 Study
- Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study)
Similar Researchers
Based on overlapping research topics
Kristin Miller
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Myocardial Infarction
Medical Research
Kunal Sarkar
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Treatment Outcome
Health and Medical Research Impacts
Malek Al‐Hawwas
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Treatment Outcome
Percutaneous Coronary Intervention
Tomas Jandik
University of Arkansas at Fayetteville
Cardiovascular Function and Risk Factors
Treatment Outcome
Health and Medical Research Impacts
Hakan Paydak
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Treatment Outcome
Medical Research
John Paul Mounsey
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Treatment Outcome
Medical Research